A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia

NCT01529515 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

509

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: PP3M 175 mg eq.
DRUG: PP3M 263 mg eq.
DRUG: PP3M 350 mg eq.
DRUG: PP3M 525 mg eq.
DRUG: Placebo (20% Intralipid emulsion)

Sponsor

Janssen Research & Development, LLC